Industries > Pharma > Gene Therapy R&D and Revenue Forecasts 2017-2027

Gene Therapy R&D and Revenue Forecasts 2017-2027

Cancer, Cardiovascular, Rare Diseases, Ophthalmologic, Other Diseases

PUBLISHED: 02 August 2017
PAGES: 127

WOOCS 2.2.1

The gene therapy market is projected to grow at a CAGR of 40.8% in the first half of the forecast period. In 2016, the cancer treatment submarket accounted for 75.0% of the gene therapy drug market. Visiongain estimated that gene therapy for rare diseases will be the driver for market growth in the second half of the forecast period.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand-new 127 page report you will receive 70 charts – all unavailable elsewhere.

The 127-page report provides clear detailed insight into the gene therapy market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Gene Therapy R&D and Revenue Forecasts 2017-2027

Report Scope

Gene Therapy market forecasts from 2017-2027

• This report assesses the approved gene therapy products in the market and gives revenue to 2027 for Neovasculgen

• Provides qualitative analysis and forecast of the submarket by indication for the period 2017-2027:
• Cancer
• Cardiovascular disorders
• Rare diseases
• Ophthalmological diseases
• Other therapeutic uses

• Profiles leading companies that will be important in the development of the gene therapy market. For each company, developments and outlooks are discussed and companies covered in this chapter include:
• UniQure
• Biogen
• Bluebird Bio
• Spark Therapeutics
• Applied Genetics Technologies Corporation
• Oxford Biomedica
• GenSight Biologics

• Assesses the outlook for the leading gene treatment R&D pipeline for 2016 and discusses technological progress and potential. Profiles appear for gene therapy drug candidates, with revenue forecasts for six leading agents:
• SPK-RPE65 (Spark Therapeutics)
• Collategene (AMG0001, AnGes MG/Vical)
• Invossa (TissueGene-C, TissueGene Inc/Kolon Life Science)
• BC-819 (BioCancell)
• Lenti-D (Bluebird Bio)
• GSK2696273 (GlaxoSmithKline)

• Provides qualitative analysis of trends that will affect the gene therapies market, from the perspective of pharmaceutical companies, during the period 2017 to 2027. SWOT analysis is provided and an overview of regulation of the gene therapy market by leading region given.

• Our study discusses factors that influence the market including these:
• Translation of research into marketable products modifying human DNA – gene transfer for therapeutic use, altering the nuclear genome
• Genomic editing technology and other supporting components
• Collaborations to develop and launch gene-based products – acquisitions and licensing deals
• Supporting technologies for human genetic modification, gene replacement and targeted drug delivery
• Gene therapies for ophthalmologic diseases – next-generation medicines
• Regulations in the United States, the European Union and Japan – overcoming technological and medical challenges to pass clinical trials.

Visiongain’s study is intended for anyone requiring commercial analyses for the gene therapy market. You find data, trends and predictions.

Buy our report today Gene Therapy R&D market Analysis : Cancer, Cardiovascular, Rare Diseases, Ophthalmologic, Other Diseases.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Gene Therapy R&D and Revenue Forecasts 2017-2027

Download sample pages

Complete the form below to download your free sample pages for Gene Therapy R&D and Revenue Forecasts 2017-2027

Latest Pharma news

Visiongain Publishes Clinical Trial Supplies Market Report 2021-2031

Deviating from protocols raises the danger of missing or delaying data collection from current investigations. This highlights the growing importance of digital medicine, which is being aided by advancements in cloud, mobile, and IoT technology.

11 October 2021


Visiongain Publishes Drug Discovery Informatics Market Report 2021-2031

High performance HPC and supercomputing technology have evolved substantially in China in the last decades, leading to extraordinary accomplishments. HPC-based and combined pharmaceutical chemical and computational biology computational discovery and design has become a significant technique in drug research and development and is sponsored financially by the Chinese government.

07 October 2021


Visiongain Publishes Pharma Wholesale and Distribution Market Report 2021-2031

Many health-care organizations are seeing organic growth at levels that their supply networks were never designed to handle. Others are frantically attempting to integrate diverse technology and procedures as part of a consolidation effort.

06 October 2021


Visiongain Publishes Meningococcal Vaccines Market Report 2021-2031

Rise in prevalence of meningitis, increasing initiatives by government and regulatory authorities coupled strong funding support from non-profit organizations is expected to drive the global meningococcal vaccines market

05 October 2021